Paxlovid: An Oral SARS-CoV-2 Mpro Inhibitor
Description
This figure illustrates the mechanism of the two components in Paxlovid, PF-07321332 and Ritonavir.
Acknowledgements
References
Owen, D. R., Allerton, C., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., Dantonio, A. L., Di, L., Eng, H., Ferre, R., Gajiwala, K., Gibson, S., Greasley, S., Hurst, B. L., Kadar, E. P., . . . Zhu, Y. (2021). An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science, 374(6575), 1586–1593. https://doi.org/10.1126/science.abl4784
Get started with this template for freeDon’t start from scratch.
Create professional scientific illustrations quickly and easily, even without any design expertise
- Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
- Create figures that effectively communicate your research in half the time using our editable icons.
- Use our PDB tool to quickly generate and customize protein structures
![example of using the icon library](https://cdn.prod.website-files.com/621e6f1effebfe03881da9bd/64c7c0fc322ef8c15744f235_ezgif.com-video-to-gif%20(1).gif)